RxDoctor Payments Data

Kenneth Etra, MD

Otolaryngology · Great Neck, NYNPI 1225012313

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 89 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$740
  • GSK$267
  • AstraZeneca$245
  • Phathom Pharmaceuticals, Inc.$198
  • Regeneron Healthcare Solutions, Inc.$179
  • Inspire Medical Systems, Inc.$155
  • plus $799 from 11 others

What the payments were for

  • Food & beverage$2,582100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,582 in reported general payments places this provider in the 65th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York

Medicare billing

Part B allowed, 2024
$688,649
Medicare patients
1,449
Services billed
8,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RyaltrisOlopatadine Hcl/Mometasone68$16,286
Ipratropium Bromide187$4,295
Mometasone Furoate191$2,600
Fluticasone Propionate184$1,931
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth17$1,915
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort40$1,712
Azelastine Hcl96$1,630
Famotidine204$1,511
Cevimeline Hcl16$1,502
Gentamicin Sulfate40$1,389
Pantoprazole Sodium109$776
Methylprednisolone89$709
Prednisone180$558
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav59$494
Omeprazole65$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USARyaltris$59$16,28668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 701 otolaryngology providers in New York.

Other otolaryngology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →